Printer Friendly

US Patent Issued for Ricolinostat to Treat Diabetic Peripheral Neuropathy.

M2 PHARMA-August 20, 2018-US Patent Issued for Ricolinostat to Treat Diabetic Peripheral Neuropathy

(C)2018 M2 COMMUNICATIONS

- US Patent No. 10,040,769 has been issued covering the use of ricolinostat (ACY-1215) for the treatment of diabetic peripheral neuropathy, US-based biopharmaceutical company Regenacy Pharmaceuticals, LLC said.

Ricolinostat is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential. The patent covering this new method of treatment was issued on August 7, 2018.

It is protected by issued US and foreign composition of matter patents with additional method-of-use patents positioned to issue for diabetic, chemotherapeutic and inherited neuropathies, as well as polycystic kidney disease.

Based on previously completed studies, ricolinostat has been proven to reverse neuropathic pain and correct metabolic defects in rat models of diabetic neuropathy, and restore impaired mitochondrial transport in neurons cultured in high glucose.

These pre-clinical findings suggest ricolinostat has the potential to be a unique, first-in-class, disease modifying treatment with the potential to restore peripheral nerve function.

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions.

The company's selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors.

Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as sickle cell disease, ?-thalassemia, leukemia, and cognitive dysfunction in neurological disorders.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 20, 2018
Words:270
Previous Article:Microbial Activity in the Mouth May Differentiate Children with Autism Spectrum Disorder, New Research Suggests.
Next Article:Navidea Biopharmaceuticals Receives Noncompliance Notice from NYSE American.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |